1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jinling Pharmaceutical Co., Ltd. Class A

Jinling Pharmaceutical Co., Ltd. Class A

SSZSE:000919
6.23
CNY
+0.07
(+1.14%)
0.09EPS
59.26P/E
3.63BMarket Cap
Jinling Pharmaceutical Co., Ltd. Class A
SZSE:000919
(Shenzhen Stock Exchange)

Recent

price

6.23

P/E

ratio

59.26

div

yld

1.73%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.29
4.48
4.57
5.17
5.5
6.39
7.1
6.33
5.75
5.03
4.97
5.57
5.3
6.34
5.54
5.14
5.13
Revenue per Share
0.38
0.33
0.28
0.31
0.39
0.41
0.36
0.27
0.48
0.29
0.13
0.24
0.21
0.21
0.07
0.09
0.1
Basic EPS, GAAP
0.16
0.18
0.09
0.25
0.41
0.21
-0.02
0.75
0.59
0.67
0.04
0.26
-0.1
-0.05
-0.08
0.03
- -
Free Cash Flow per Basic Share
0.15
0.16
0.18
0.19
0.18
0.18
0.18
0.18
0.25
0.17
0.18
0.1
0.1
0.1
0.11
0.11
0.11
Dividend per Share
3.9
4.08
4.21
4.37
4.6
4.85
5.04
5.13
5.59
5.71
5.67
5.81
5.87
6.33
6.08
6.07
6.06
Book Value per Share
3.73
3.91
3.92
4.08
4.17
4.4
4.6
4.7
4.87
5.18
5.25
5.5
5.31
5.37
5.46
5.48
5.48
Tangible Book Value per Share
504
504
504
504
504
504
504
504
504
504
504
504
504
504
593
622
622
Basic Weighted Avg Shares
2,161
2,257
2,305
2,606
2,772
3,221
3,579
3,192
2,899
2,535
2,504
2,809
2,671
3,194
3,281
3,197
3,193
Sales/Revenue/Turnover
11.9
11.54
8.34
8.6
8.88
7.7
7.55
6.6
7.21
7.78
7.25
6.29
2.34
3.03
1.22
1.13
1.52
Operating Margin (%)
59
60
66
80
84
101
108
116
123
122
120
123
124
151
161
161
- -
Depreciation Expense
193
165
144
156
197
208
180
137
242
145
65
121
105
106
40
54
61
Net Income, GAAP
14.71
19.07
19.92
21.53
19.62
20.41
21.17
20.75
20.1
25.76
25.15
21.5
10.88
13.21
55.12
21.32
23.97
Effective Tax Rate (%)
8.92
7.32
6.23
5.98
7.11
6.46
5.03
4.3
8.34
5.73
2.6
4.29
3.94
3.32
1.23
1.69
1.92
Profit Margin (%)
1,447
1,546
1,307
1,378
1,358
1,518
1,652
1,594
1,649
1,569
1,247
1,433
1,768
2,007
2,591
2,822
2,763
Working Capital
17
16
14
32
11
10
9
7
- -
- -
1
1
2
39
185
183
183
LT Debt
2,199
2,325
2,466
2,574
2,751
2,925
3,053
3,054
3,331
3,425
3,433
3,535
3,627
4,412
4,849
4,822
4,816
Total Equity
10.66
8.81
6.84
7.21
8.6
8.57
7.18
5.57
8.91
5.42
2.72
4.4
3.19
3.14
0.4
1.08
1.24
Return on Invested Capital (%)
7.13
5.28
4.6
4.88
5.55
5.39
4.63
3.43
6.03
3.18
1.08
2.53
2.7
2.07
1.35
1.21
1.37
Return on Capital (%)
10.11
8.22
6.87
7.21
8.72
8.74
7.23
5.35
8.95
5.1
2.27
4.17
3.56
3.41
1.15
1.42
1.61
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
9
9
9
LT Borrowings
150
150
150
LT Finance Leases
33
33
33
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
622
622
622
Market Capitalization
4,944
4,465
3,626

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,798
3,752
3,730
Cash, Cash Equivalents & STI
2,456
2,477
2,640
Accounts Receivable, Net
408
511
390
Inventories
233
220
202
Total Current Liabilities
976
955
967
Payables & Accruals
- -
- -
- -
ST Debt
9
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.31%
7.31%
-0.55%
Free Cash Flow
-333.22%
61.66%
-134.45%
Net Income, GAAP
-1.13%
8.96%
33.42%
Sales/Revenue/Turnover
0.43%
5.41%
-2.56%
Total Cash Common Dividend
- -
-2.51%
6.75%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
846
764
709
1,061
3,281
2025
810
791
- -
817
3,197
2026
769
816
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.01
0.03
-0.05
0.07
2025
0.04
0.04
- -
-0.02
0.09
2026
0.04
0.04
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.1
- -
- -
0.11
2025
- -
0.01
- -
- -
0.11
2026
- -
0.1
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jinling Pharmaceutical Company Limited (000919.SZ) manufactures and sells pharmaceutical products, medical devices, and provides medical care services in China. The company offers Mailuoning (Choronin) injection and oral solutions for treating thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, and thrombophlebitis; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; shiitake mushroom polysaccharide (lentinan) injection for malignant tumors; and absorbable gelatin sponge for wound hemostasis; as well as biochemical products, pharmaceutical packaging, and natural beverages. It operates a "pharmaceutical industry + medical care" layout through manufacturing and hospital services, primarily targeting domestic markets with a focus on East China. Founded in 1998 and headquartered at Jinling Pharmaceutical Building, No. 238 Zhongyang Road, Nanjing, Jiangsu Province, China, the company listed on the Shenzhen Stock Exchange main board in 1999. Its medical care segment includes operations through subsidiaries such as Nanjing Meishan Hospital. Recent developments include signing a RMB 78.5 million technology transfer contract with Nanjing Drum Tower Hospital in October 2025 to advance innovation. In November 2025, its controlling subsidiary Nanjing Meishan Hospital announced plans to invest RMB 893 million in a hospital expansion and renovation project to enhance medical facilities and service capacity. The company also agreed to acquire a 43.6% stake in Nanjing Meishan Hospital and, in 2025, cancelled a prior plan to acquire a 60% stake in the Third Affiliated Hospital of Nanjing Medical University while proceeding with the liquidation of wholly-owned subsidiary Bangjian Tianfeng to optimize resources.